[The Impact of CD4+/CD8+ Ratio on the Efficacy of CAR-T Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma].
To evaluate the predictive value of peripheral blood CD4+/CD8+ ratio immediately prior to chimeric antigen receptor T-cell (CAR-T) infusion (Day 0) for treatment efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
A retrospective analysis was conducted on data from 49 R/R DLBCL patients who received CAR-T therapy at The First Affiliated Hospital of Soochow University between January 2017 and June 2024. The relationship between the Day 0 peripheral blood CD4+/CD8+ ratio and treatment efficacy was evaluated.
At 3 months post-CAR-T infusion, the objective response rate of the 49 patients was 75.5% (37/49), comprising a complete response rate of 55.1% (27/49) and a partial response rate of 20.4% (10/49). Patients with a Day 0 peripheral blood CD4+/CD8+ ratio ≥1 had a significantly higher 90-day response rate than those with a ratio <1 (88.2% vs. 46.7%, P =0.002). Multivariate analysis showed that the Day 0 peripheral blood CD4+/CD8+ ratio was an independent predictor of both progression-free survival (PFS) and overall survival (OS) (P =0.025； P =0.037). Patients with a ratio ≥1 had significantly longer median PFS (11.0 vs. 3.0 months, P =0.011) and median OS (32.1 vs. 8.5 months, P =0.003) compared to those with a ratio <1.
Peripheral blood CD4+/CD8+ ratio ≥1 immediately prior to CAR-T infusion can predict a higher CAR-T treatment response rate and superior survival outcomes in R/R DLBCL patients.
A retrospective analysis was conducted on data from 49 R/R DLBCL patients who received CAR-T therapy at The First Affiliated Hospital of Soochow University between January 2017 and June 2024. The relationship between the Day 0 peripheral blood CD4+/CD8+ ratio and treatment efficacy was evaluated.
At 3 months post-CAR-T infusion, the objective response rate of the 49 patients was 75.5% (37/49), comprising a complete response rate of 55.1% (27/49) and a partial response rate of 20.4% (10/49). Patients with a Day 0 peripheral blood CD4+/CD8+ ratio ≥1 had a significantly higher 90-day response rate than those with a ratio <1 (88.2% vs. 46.7%, P =0.002). Multivariate analysis showed that the Day 0 peripheral blood CD4+/CD8+ ratio was an independent predictor of both progression-free survival (PFS) and overall survival (OS) (P =0.025； P =0.037). Patients with a ratio ≥1 had significantly longer median PFS (11.0 vs. 3.0 months, P =0.011) and median OS (32.1 vs. 8.5 months, P =0.003) compared to those with a ratio <1.
Peripheral blood CD4+/CD8+ ratio ≥1 immediately prior to CAR-T infusion can predict a higher CAR-T treatment response rate and superior survival outcomes in R/R DLBCL patients.